The future of drug development in urothelial cancer

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 473-475

  Dreicer, Robert ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEMCITABINE; PACLITAXEL; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE MARROW SUPPRESSION; CARCINOGENESIS; DEEP VEIN THROMBOSIS; DRUG DEVELOPMENT; EDITORIAL; GENE MUTATION; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84856834094     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.5566     Document Type: Editorial

References (16)

1. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract - A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985 (Pubitemid 16246757)
2. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407, 1985 (Pubitemid 15129797)
3. Garcia JA, Dreicer R: Systemic chemotherapy for advanced bladder cancer: Update and controversies. J Clin Oncol 24:5545-5551, 2006 (Pubitemid 46631335)
4. Choueiri TK, Ross RW, Jacobus S, et al: Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30:507-512, 2012
5. Cheng L, Zhang S, MacLennan GT, et al: Bladder cancer: Translating molecular genetic insights into clinical practice. Hum Pathol 42:455-481, 2011
6. Lönn U, Lönn S, Friberg S, et al: Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1:1189-1194, 1995
7. Jimenez RE, Hussain M, Bianco FJ Jr, et al: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447, 2001 (Pubitemid 32751647)
8. Pinto A, Redondo A, Zamora P, et al: Angiogenesis as a therapeutic target in urothelial carcinoma. Anticancer Drugs 21:890-896, 2010
9. Laé M, Couturier J, Oudard S, et al: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann Oncol 21:815-819, 2010
10. Caner V, Turk NS, Duzcan F, et al: No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 14:261-266, 2008
11. Hussain MH, MacVicar GR, Petrylak DP, et al: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218-2224, 2007 (Pubitemid 46954646)
12. Chakravarti A, Winter K, Wu CL, et al: Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62:309-317, 2005 (Pubitemid 40704444)
13. Iyer G, Milowsky MI, Bajorin DF: Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev Anticancer Ther 10:1917-1932, 2010
14. Hahn NM, Stadler WM, Zon RT, et al: Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 29:1525-1530, 2011
15. Smith SC, Baras AS, Lee JK, et al: The COXEN principle: Translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 70:1753-1758, 2010
16. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009